Financing

#Biologics / Biotechnology #Cell therapy #CNS #Financing #Kenai Therapeutics #Neurology #Parkinson's

$82m investment in cell therapies for neurological diseases

Biotechnology company Kenai Therapeutics has raised $82 million in a Series A financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group. Kenai Therapeutics previously raised seed funding under the name Ryne Bio. “We are grateful for the support of a… Read More

#Business & Investment #News

#Autoimmune disease #Biologics / Biotechnology #COUR Pharmaceuticals #Financing #Investment

$105 million raised to support therapies for autoimmune diseases

COUR Pharmaceuticals has secured $105 million in a Series A investment round co-led by Lumira Ventures and Alpha Wave Ventures. The funds will be used to support the advancement of COUR’s myasthenia gravis (MG) and type 1 diabetes (T1D) product candidates into Phase IIa clinical trials. Read More

#Business & Investment #News

Business financing
#Drug discovery #Financing #Obesity #Phase I trial #Resalis Therapeutics

€10M financing to support disease-modifying obesity drug

Italy-based Resalis Therapeutics has closed a €10 million ($11 million) Series A financing round led by Sunstone Life Science Ventures with participation from existing investors. The company intends to use the proceeds to initiate and complete the first-in-human Phase I clinical trial and reach Phase II… Read More

#Business & Investment #News

#Contract Research Organisations (CROs) #Financing #Funding #Metrion Biosciences

Ion-channel specialist CRO closes £3.7m in new equity financing

Metrion Biosciences has secured £3.5m ($4.4m) in new equity financing, which will be used to further expand the company’s laboratories in Cambridge, UK, invest in specialist equipment and enhance global marketing activities. The investment includes £2.5m from lead investor Maven Capital Partners and £1 million Gresham… Read More

#Business & Investment #News

Monoclonal antibodies
#Anti-inflammatory #Financing #Lassen Therapeutics #Monoclonal antibodies #Ophthalmology

$85m fund supports monoclonal antibody for fibro-inflammatory disorders

Antibody therapeutics company Lassen Therapeutics has closed an oversubscribed $85 million Series B financing. The proceeds will fund a Phase II study in thyroid eye disease (TED) with the company’s monoclonal antibody LASN01 and the continued development of LASN500 for cancer. The clinical programme… Read More

#Business & Investment #News

Business financing
#Cancer immunotherapy #Cancer vaccine #Financing #Immunotherapy #Nouscom #Oncology

Cancer immunotherapy company raises €67.5 million

Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalised viral vector-based cancer vaccines, has raised €67.5 million in an oversubscribed Series C financing round. The proceeds will enable Nouscom to advance its pipeline and complete Phase II clinical trials with its cancer vaccine NOUS-209. Read More

#Business & Investment #News

MRI of the brain
#Alzheimer's #AstronauTx #Financing #Neurodegenerative disorders #University College London

UCL spinout raises £48m funding for new approach to Alzheimer’s

University College London (UCL) spinout AstronauTx has closed a £48m ($61m) Series A financing to develop novel treatments for Alzheimer’s disease and other neurodegenerative disorders. The company was launched in 2019, initially to build on research from the Alzheimer’s Research UK UCL Drug Discovery Institute (UCL… Read More

#Business & Investment #News

Seed fund
#BioInnovation Institute #Financing #Mental health #Plant-based #Start-ups

$3M funding for plant-inspired halogenated small molecule drugs

Biomia, the first company spun out from BioInnovation Institute’s Bio Studio programme, has secured $3 million in pre-seed financing from an international syndicate of investors. Biomia says it plans to use the investment to accelerate its development of plant-inspired natural and new-to-nature halogenated small molecule drug… Read More

#Business & Investment #News #Start-up Zone

Monoclonal antibodies
#AbolerIS Pharma #Arthritis #Autoimmune disease #Financing #Monoclonal antibodies

€27.3M to advance monoclonal antibody for autoimmune diseases

AbolerIS Pharma has raised €27.3 million in a Series A financing led by Caixa Capital Risc and co-led by Sound Bioventures and Newton Biocapital. Proceeds from the financing will enable AbolerIS to accelerate the development of its lead programme in clinical trials and explore its effectiveness… Read More

#Business & Investment #News

AI brain
#Artificial intelligence (AI) #Financing #Funding #Genesis Therapeutics

AI drug discovery company closes $200m Series B financing

A Series B financing round has raised Genesis Therapeutics’ total capital to over $280 million, which will be used to bring the company’s artificial intelligence (AI)-enabled pipeline into clinical development. Genesis will also invest in continued development of generative and predictive AI methods, which form the… Read More

#Business & Investment #News

Great British Pounds, Investment
#ABPI #BioIndustry Association #Biologics / Biotechnology #Clarivate #Financing #Investment #UK

UK biotech financing up 29% on last quarter

The second quarter of 2023 has seen steady growth in financing activity for the UK’s life sciences sector, according to new data released by the BioIndustry Association (BIA) and Clarivate. The positive news comes soon after industry figures welcomed recent announcements to unlock new sources of… Read More

#Business & Investment #News

Scientist in laboratory
#Cancer research #Crescendo Biologics #Financing #Oncology #Phase I trial #Solid tumours

Crescendo secures $32M to expand Phase Ib trial in solid tumours

Immuno-oncology company Crescendo Biologics has revealed plans to augment the ongoing Phase Ib clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort. Additional financing of $32 million has been secured with the support of all major existing shareholders, including Sofinnova… Read More

#Cancer Research #News

#Camena Bioscience #Financing #Funding #Genetics / genomics #Synthetic biology

Synthetic biology company raises $10m in financing round

Camena Bioscience has closed a $10m Series A financing round, which will be used to scale operations and continue development of DNA synthesis platform gSynth. Synthetic genes are widely used by researchers to understand the mechanisms of disease, and in the drug discovery process to combat… Read More

#News

Scientist looking through microscope
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Automation / robotics #Financing #Fundraising #Iktos #Investment

AI and robotics drug discovery company raises €15.5M

Iktos has raised €15.5m in a Series A funding round to expand its artificial intelligence-based drug discovery technologies and solutions. The round was co-led by new investors M Ventures and Debiopharm Innovation Fund with participation from Omnes Capital. The financing will enable the company… Read More

#Business & Investment #News

#ALS #Cerevance #Financing #Funding #Neurology #Parkinson's #Schizophrenia

$116 million financing will support neurological disease trials

Cerevance has expanded its Series B funding round with an additional close of $51 million, bringing the total to $116 million.  The financing will support upcoming clinical trials focused on Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), and schizophrenia.   “We are thrilled to secure additional funding… Read More

#Business & Investment #News